Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Cytek Biosciences, Inc. before investing. In this article, we go over a few key ...

Interested parties may access live and archived webcasts of the presentations for the Stephens and Piper Sandler events referenced above on the “Investors” section of the company website at: investors ...

Cytek Biosciences, Inc. ((CTKB)) has held its Q3 earnings call. Read on for the main highlights of the call. The recent earnings call of Cytek Biosciences, Inc. presented a mixed sentiment, reflecting ...

FREMONT, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Cytek ® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial ...

“Our third quarter results are encouraging and demonstrate the strength of our established brand and technology and our market leadership position,” said Wenbin Jiang, CEO of Cytek Biosciences. “As we ...

FREMONT, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Amid the reduction of various government grant programs and global economic challenges that have tightened research funding, Cytek Biosciences, Inc. ...

Cytek Biosciences has reported relatively small net losses, indicating that its financial position has not deteriorated significantly. In Q2 2025, the company had liquid assets of $262.02 million.